Key Performance
More- Earnings Score: N/A
- Momentum Score: 45
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
A class action lawsuit has been filed against Tenax Therapeutics for alleged securities fraud. The complaint alleges that the company made materially false and misleading statements regarding its lead clinical program TNX-103, overstating its effectiveness and commercial prospects. Investors who purchased Tenax securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses, with a lead plaintiff deadline of December 28, 2026.
11/11/2026, 11:00 AM • GlobeNewswire
Several class action lawsuits have been filed against publicly traded companies alleging securities fraud and violations of federal securities laws. Endava plc faces allegations of false statements regarding accounting treatment and internal control effectiveness. Additional lawsuits target Tenax Therapeutics, D-Wave Quantum, FuelCell Energy, Lincoln Educational Services, and Baidu, with various lead plaintiff deadlines in November and December 2026.
11/08/2026, 12:00 PM • GlobeNewswire
Several class action lawsuits have been filed against publicly traded companies alleging securities fraud and misleading statements to investors. Tenax Therapeutics faces claims regarding overstated effectiveness of its lead clinical program TNX-103. Additional lawsuits target D-Wave Quantum, Compass Inc., FuelCell Energy, Lincoln Educational Services, and Baidu, with various lead plaintiff deadlines in November and December 2026.
11/08/2026, 11:00 AM • GlobeNewswire
Rosen Law Firm is investigating potential securities claims against Fervo Energy Company (NASDAQ: FRVO) for allegedly issuing materially misleading business information. The firm is preparing a class action lawsuit to recover investor losses. Additional class actions are also being pursued against Yiren Digital Ltd., Tenax Therapeutics, Inc., Better Home & Finance Holding Company, and AppLovin Corporation.
11/07/2026, 11:26 AM • GlobeNewswire
Rosen Law Firm is reminding investors who purchased Tenax Therapeutics securities between November 13, 2023 and August 7, 2026 to join a securities class action lawsuit before the December 28, 2026 lead plaintiff deadline. The lawsuit alleges that Tenax made materially false and misleading statements about TNX-103's effectiveness and commercial prospects, causing investor damages when the true details emerged.
11/07/2026, 8:51 AM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Tenax Therapeutics (TENX), Fluence Energy (FLNC), and AST SpaceMobile (ASTS) on behalf of investors who purchased securities during specified periods. The lawsuits allege materially false and misleading statements regarding product effectiveness and commercial prospects. Investors with losses are encouraged to secure counsel before upcoming deadlines.
11/04/2026, 8:03 PM • GlobeNewswire
A class action lawsuit has been filed against Tenax Therapeutics (NASDAQ: TENX) alleging that the company made materially false and misleading statements regarding its lead clinical program TNX-103, overstating its effectiveness and commercial prospects. Investors who purchased securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses, with a lead plaintiff deadline of December 28, 2026.
11/04/2026, 11:00 AM • GlobeNewswire
A class action lawsuit has been filed against Tenax Therapeutics for alleged securities fraud. The complaint alleges that the company made materially false and misleading statements regarding its lead clinical program TNX-103, overstating its effectiveness and commercial prospects. Investors who purchased TENX securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses, with a lead plaintiff deadline of December 28, 2026.
11/01/2026, 11:00 AM • GlobeNewswire
Rosen Law Firm has filed class action lawsuits on behalf of investors in Tenax Therapeutics, Inc. (TENX), alleging the company made materially false and misleading statements regarding the effectiveness of its drug TNX-103 and overstated its clinical, regulatory, and commercial prospects. The lead plaintiff deadline is December 28, 2026. Similar lawsuits have been filed against Tigo Energy, Inc. (TYGO) and FuelCell Energy, Inc. (FCEL).
11/01/2026, 10:43 AM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against multiple companies including Tigo Energy, Tenax Therapeutics, and FuelCell Energy. The Tigo Energy lawsuit alleges the company made materially false statements regarding revenue projections based on an EG4 partnership that would not materialize until Q4 2026 at the earliest. Investors who purchased securities during specified class periods are encouraged to seek counsel before upcoming deadlines.
11/01/2026, 10:22 AM • GlobeNewswire
Robbins LLP has filed class action lawsuits against O-I Glass, Inc. for misleading investors about its 2026 financial outlook and Fit to Win program, Everest Group, Ltd. for aggressive expansion and false risk management assurances, and Tenax Therapeutics, Inc. for misrepresenting the viability of its drug candidate levosimendan. O-I Glass stock declined 15% after the company reduced its 2026 guidance on July 29, 2026.
10/30/2026, 8:34 PM • GlobeNewswire
Robbins LLP announced class action lawsuits against Everest Group, Ltd. for allegedly misleading investors about its U.S. casualty insurance business risks and reserve adequacy. The lawsuit covers purchases between February 2024 and October 2025, with Everest's stock declining significantly after disclosures of $478 million in unfavorable reserve development and a $1.2 billion protection agreement. Additional class actions were filed against O-I Glass, Inc. for misrepresenting financial outlook and Tenax Therapeutics, Inc. for misleading claims about its drug candidate levosimendan.
10/30/2026, 8:18 PM • GlobeNewswire
Robbins LLP announces a class action lawsuit against Tenax Therapeutics for allegedly misleading investors about the viability of its drug candidate levosimendan. The company's Phase 3 LEVEL trial failed to meet its primary endpoint, causing the stock to plummet 89.77% on August 10, 2026. Investors have until December 28, 2026 to seek lead plaintiff status.
10/30/2026, 8:18 PM • GlobeNewswire
Rosen Law Firm announced investigations into potential breaches of fiduciary duties by directors and officers at Monolithic Power Systems, Barclays PLC, and Tenax Therapeutics. The firm is seeking shareholders who have suffered losses to join class action lawsuits.
10/29/2026, 6:38 PM • GlobeNewswire
A class action lawsuit has been filed against Tenax Therapeutics (NASDAQ: TENX) alleging that the company made materially false and misleading statements regarding its lead clinical program TNX-103, overstating its effectiveness and commercial prospects. Investors who purchased TENX securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses, with a lead plaintiff deadline of December 28, 2026.
10/28/2026, 11:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 11/11/2026
Company Profile
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.